Trials / Withdrawn
WithdrawnNCT00414089
Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL
Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AHS Cancer Control Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see how well Zevalin works in the treatment of low grade indolent B-cell lymphoma when given to patients who have not had any previous treatment for their lymphoma and who otherwise would be followed on a "watch \& wait" policy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 90Y-ibritumomab tiuxetan (Zevalin) |
Timeline
- First posted
- 2006-12-21
- Last updated
- 2016-02-15
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00414089. Inclusion in this directory is not an endorsement.